Determination of Prostatic Specific Antigen (PSA) Level in Patients with Polycystic Ovary Syndrome (PCOS)
Authors/Creators
- 1. Department of Biochemistry, Post Graduate Student, Jhalawar Medical College, Jhalawar, Rajasthan
- 2. Department of Biochemistry, Senior Professor, Jhalawar Medical College, Jhalawar, Rajasthan
- 3. Department of Biochemistry, Professor& Head, Jhalawar Medical College, Jhalawar, Rajasthan
Description
Introduction: The polycystic ovary syndrome (PCOS) is a reproductive endocrine disorder, clinically characterized by oligo-ovulation/chronic anovulation, menstrual irregularities and hyperandrogenism. Objectives: The aim of this study was determined and compare the concentration PSA in 50 patients with PCOS and 50 healthy female controls. Result: The present observation showed that the mean level of PSA concentration in case (group I) was found to be (0.84 ± 0.30 ng/ml) and in control (group II) was found to be (0.53 ± 0.29 ng/ml). Statistical analysis showed that p < 0.05. Conclusion: The PSA concentration in PCOS patient was found to be higher than that of healthy controls, and the difference was statistically significant. A comparatively elevated PSA level in PCOS women as compared to normal women is an indication of hyperandrogenism.
Abstract (English)
Introduction: The polycystic ovary syndrome (PCOS) is a reproductive endocrine disorder, clinically characterized by oligo-ovulation/chronic anovulation, menstrual irregularities and hyperandrogenism. Objectives: The aim of this study was determined and compare the concentration PSA in 50 patients with PCOS and 50 healthy female controls. Result: The present observation showed that the mean level of PSA concentration in case (group I) was found to be (0.84 ± 0.30 ng/ml) and in control (group II) was found to be (0.53 ± 0.29 ng/ml). Statistical analysis showed that p < 0.05. Conclusion: The PSA concentration in PCOS patient was found to be higher than that of healthy controls, and the difference was statistically significant. A comparatively elevated PSA level in PCOS women as compared to normal women is an indication of hyperandrogenism.
Files
IJTPR,Vol14,Issue1,Article40.pdf
Files
(345.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:fa6a4b6fbe5c67e07be37e288ff87943
|
345.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-11-13
Software
References
- 1. GuzickD. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol. 1998;179:89–93. 2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9): 3078–82. 3. Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol. 2010;26(4):281–96. 4. Vural B, Ozkan S, Bodur H. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome? J ObstetGynaecol Res. 2010;33(2): 166–73. 5. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. FertilSteril 2003 ; 80: 252–254. 6. Lobo RA. What are the key features of importance in polycystic ovary syndrome? FertilSteril 2003; 80: 259-261. 7. Escobar-Morale HF, Serrano-Gotarredona J, Avila S, VillarPalasi J, Varela C, Sancho J. The increased circulating prostatespecific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998; 83: 2580–2584. 8. Burelli A, Cionini R, Rinaldi E et al. Serum PSA levels are not affected by the menstrual cycle or the menopause but are increased in subjects with polycystic ovary syndrome. J Endocrinol Invest 2006; 29: 308–312. 9. Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostatespecific antigen gene expression in breast cancer. Br J Cancer. 1997; 75:579–88. 10. Gullu S, Emral R, Asik M, et al. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Investig. 2003; 26:1198. 11. Negri C, Tosi F, Dorizzi R, et al. Antiandrogen drugs lower serum PSA levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000;85:81–4. 12. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem. 1996;271: 6379– 88. 13. Yu H, Diamandis EP, Monne M, Croce CM. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem. 1995;270:6615–8. 14. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamantidis EP. Prostatespecific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab. 1997;82:777–80. 15. ArezooMaleki-Hajiagha et al; Serum ProstateSpecific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis; HormMetab Res 2019; 51: 230–242 16. EwaRudnicka, Stanislaw Radowicki et al. Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome. Gynecological Endocrinology. 2016-07-19; 1473-0766; DOI: 10.1080/ 09513590. 2016.1200552 17. FarahnazMardanian, Nasrin Heidari. Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. J Res Med Sci. 2011-07-24; ; 16(8): 999-1005 18. Katsaros D, Melegos DN, Diamandis EP. Prostate-specific antigen production by breast tumors after induction with oral contraceptives. Clin Biochem 1998; 31: 285–288. 19. Goh VHH. Breast tissues in transexual womena nonprostatic source of androgen upregulated production of prostatespecific androgen. J Clin Endocrinol Metab 1999; 84: 3313– 3315.